[{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"CYP450-3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Formycon"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"ACh-alpha-4\/beta-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Acetate","moa":"Carbonic anhydrase-1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganirelix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Formycon"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Fresenius SE & Co. KGaA
Details :
Epinephrine is a non-selective alpha- and beta-adrenergic agonist, which is indicated for the treatment of hypotension associated with septic shock & anaphylaxis.
Details :
Otulfi (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.
Details :
Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Details :
Tyenne (tocilizumab) is an IL-6 antagonist, an autoinjector, available as both IV and SC. It is approved for RA, giant cell arteritis, polyarticular JIA, systemic JIA, and cytokine release syndrome.
Details :
Noxafil-Generic (posaconazole) is a CYP451 inhibitor drug, which is indicated for invasive aspergillosis in adults and pediatric patients 13 years of age and older and candida infections.
Details :
Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Details :
Tyenne (tocilizumab biosimilar) is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Details :
Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.
Reset All
